Skip to main content
. 2014 Jul 21;2014(7):CD009285. doi: 10.1002/14651858.CD009285.pub3

Min 2006.

Methods Design: 12 weeks, double‐blind, randomised, placebo‐controlled, parallel group study
Participants Population: 43 patients
Inclusion criteria: FEV1/FVC ≤ 0.70, FEV1 ≥ 30% predicted
Interventions 1. Tiotropium 18 mcg once daily
2. Placebo once daily
Outcomes FEV1, FVC, FEV1/FVC, FEV1%, safety
Notes